Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a cheap pill replace IV drips for ulcer bleeding?

NCT ID NCT04394663

Disease control Sponsor: King Chulalongkorn Memorial Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study compares high-dose oral omeprazole (a common acid-reducing pill) against standard intravenous pantoprazole (given through a vein) in 128 adults who have had a bleeding stomach ulcer treated with endoscopy. The goal is to see if the oral pill is just as good at preventing rebleeding over 3 days. If it works, it could simplify treatment and lower costs.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
omeprazole (oral) and pantoprazole (intravenous)
What this could lead to
If successful, this could show that a cheaper, easier-to-take oral medication is just as effective as an IV drip for preventing ulcer rebleeding after endoscopy.
What could go wrong
This is a small, early-phase trial (128 participants) testing a non-inferiority hypothesis, so results may not apply broadly. The oral drug may not control stomach acid as consistently as the IV drip.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 128 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2020

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with peptic ulcer bleeding and endoscopic finding show ulcer with Forrest classification Ia (spurting haemorrhage), IIa (oozing haemorrhage), Ib (non-bleeding visible vessel) * Age \> 18 years old Exclusion Criteria: * Deny to participate * Pregnancy or lactation * Low risk peptic ulcer bleeding including clean base ulcer, flat pigmented spot * Non-peptic ulcer bleeding eg. erosive gastritis/duodenitis, Mallory Weiss tear, esophageal/gastric/duodenal varices, vascular lesions (eg. Dieulafoy) , malignant ulcer * Bleeding tendency * Terminal stage of cancer * ESRD on hemodialysis * Decompensated liver cirrhosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gi bleeding are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Gastrointestinal Hemorrhage peptic ulcer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gi bleeding

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • King Chulalongkorn Memorial Hospital

    RECRUITING

    Pathum Wan, Bangkok, 10330, Thailand

  • Surin Hospital

    RECRUITING

    Surin, 32000, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.